This ensures researchers can study GLP-1 therapies in populations that reflect real-world diversity, accounting for variations in age, ethnicity, socioeconomic status, and comorbid conditions
Otto, T
Failure to Document Side Effects: Include detailed side effect symptoms and relevant ICD-10 codes (e.g., T38.3X5A, T38.3X5D) for adverse reactions
Most patients experience a reduction in appetite, which helps them make healthier food choices and may contribute to gradual weight loss
A few mechanisms that don't reduce neatly to mesolimbic dopamine: (1) conditioned aversion, GLP-1 activation engages nausea/malaise circuits, so some of the reduction in substance use may reflect aversive conditioning rather than reward modulation per se
She's the Chief Science Officer of Novo Nordisk and it's Lotte Bjerre Knudsen, and we're delighted to have her